Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Diabetes mellitus is a predictor of the severe course of a new coronavirus infection and high mortality, in this regard, the selection of appropriate hypoglycemic therapy is a vital issue. In this article, we paid attention to dipeptidyl peptidase-4 (DPP-4) inhibitors, since this group of drugs has features like low risk of hyperglycemia and immuno-mediated effects. For the most effective treatment, it is necessary to take into account the individual characteristics of each patient, namely, the achievements of pharmacogenetics. The genetic variability of the response to therapy with DPP-4 inhibitors is due to a variety of polymorphisms, several main variations are considered in the review. The ambiguity of the available studies on the effectiveness of DPP-4 inhibitors in patients with type 2 diabetes with COVID-19 indicates the need to continue pharmacogenetic studies. The combination of knowledge about the subtleties of the mechanisms of pharmacological action of drugs and individual characteristics of pharmacodinamics will ensure the greatest effectiveness and safety of personalized therapy of diabetes mellitus against the background of coronavirus infection.

About the authors

Konstantin G. Gurevich

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: kgurevich@mail.ru
ORCID iD: 0000-0002-7603-6064
SPIN-code: 4344-3045

Dr. Sci. (Med.), Professor, Head of the UNESCO Department “A healthy lifestyle is a guarantee of progress”, faculty of Pedagogical education at the higher medical school

Russian Federation, 20/1 Delegatskaya st., Moscow, 103473

Yulia A. Sorokina

Privolzhsky Research Medical University

Email: zwx@inbox.ru
ORCID iD: 0000-0001-8430-237X

Cand. Sci. (Biol.), Assistant Professor of the General and Clinical Pharmacology Department

Russian Federation, Nizhnii Novgorod

Alexander L. Urakov

Izhevsk State Medical Academy

Email: urakoval@live.ru
ORCID iD: 0000-0002-9829-9463
SPIN-code: 1613-9660

Dr. Sci. (Med.), Professor, Head of the Department of General and Clinical Pharmacology

Russian Federation, Izhevsk

Snezhana D. Sinyushkina

Privolzhsky Research Medical University

Email: ss.snowflake@yandex.ru

student

Russian Federation, Nizhnii Novgorod

Maria I. Pryazhnikova

Privolzhsky Research Medical University

Email: masha.p21@mail.ru

student

Russian Federation, Nizhnii Novgorod

Alyona V. Gorinova

Privolzhsky Research Medical University

Email: alena_gorinova@mail.ru

student

Russian Federation, Nizhnii Novgorod

Lyubov V. Lovtsova

Privolzhsky Research Medical University

Email: lovcovalubov@mail.ru

Dr. Sci. (Med.), Assistant Professor of the General and Clinical Pharmacology Department

Russian Federation, Nizhnii Novgorod

Olga V. Zanozina

Privolzhsky Research Medical University

Email: zwx2@mail.ru
ORCID iD: 0000-0003-1830-3600

Dr. Sci. (Med.), Professor of the Department of Hospital Therapy

Russian Federation, Nizhnii Novgorod

References

  1. Verspohl EJ. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009;124(1): 113–138. doi: 10.1016/j.pharmthera.2009.06.002
  2. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6): 992–1019. doi: 10.1210/er.2014-1035
  3. Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy — focus on alogliptin. Drug Des Devel Ther. 2013;7:989–1001. doi: 10.2147/DDDT.S37647
  4. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4):919–931. doi: 10.1185/030079906X162746
  5. Kimura T, Kaku K. New prospects for incretin-related drugs in the treatment of type 2 diabetes. J Diabetes Investig. 2021;12(7): 1141–1143. doi: 10.1111/jdi.13460
  6. Tasyurek HM, Altunbas HA, Balci MK, et al. Incretins: Their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev. 2014;30(5):354–337. doi: 10.1002/dmrr.2501
  7. Han SJ, Ha KH, Lee N, et al. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study. Diabetes Obes Metab. 2021;23(3):682–691. doi: 10.1111/dom.14261
  8. Espeland MA, Pratley RE, Rosenstock J, et al. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes Obes metab. 2021;23(2):569–580. doi: 10.1111/dom.14254
  9. Zanozina OV, Sorokina YuA, Lovtsova LV, et al. Gliptiny v inkretin-napravlennoi farmakoterapii sakharnogo diabeta: vozmozhnosti i personalizatsiya. Nizhnii Novgorod: Remedium Privolzh’e; 2018. 112 p. (In Russ.) doi: 10.21145/978-5-906125-57-6_2018
  10. Lotfy M, Singh J, Kalász H, et al. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. The open medicinal chemistry journal. 2011;5(2):82–92. doi: 10.2174/1874104501105010082
  11. Szeltner Z, Polgar L. Structure, function and biological relevance of prolyl oligopeptidase. Curr Protein Pept Sci. 2008;9(1):96–107. doi: 10.2174/138920308783565723
  12. Urakov AL, Gurevich KG, Sorokina YuA, et al. Metformin and vildagliptin combination: a new approach of endothelial nitric oxide synthase activity regulation and metabolism in diabetes mellitus type 2. Reviews on Clinical Pharmacology and Drug Therapy. 2018;16(2):5–12. (In Russ). doi: 10.17816/RCF1625-12
  13. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:80. doi: 10.3389/fendo.2019.00080
  14. Reinhold D, Bank U, Täger M, et al. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci. 2008;13(6):2356–2363. doi: 10.2741/2849
  15. Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes Metab. 2021;47(2):101213. doi: 10.1016/j.diabet.2020.11.005
  16. Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021;20(1):543–550. doi: 10.1007/s40200-021-00777-4
  17. Sorokina YuA, Zanozina OV, Postnikova AD. The insulin resistance indices: necessity and opportunities in type 2 diabetes mellitus management. Clinical Medicine. 2020;98(7):529–535. (In Russ.) doi: 10.30629/0023-2149-2020-98-7-529-535
  18. Tomovic K, Lazarevic J, Kocic G, et al. Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection. Med Res Rev. 2019;39(1):404–422. doi: 10.1002/med.21513
  19. Liu X, Men P, Wang B, et al. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids in Health and Disease. 2019;18(1):144. doi: 10.1186/s12944-019-1086-4
  20. Makarova EV, Varvarina GN, Sorokina YuA, et al. Metformin opportunities in comorbid patents with diabetes mellitus type 2 and chronic obstructive pulmonary disease. Dnevnik kazanskoi meditsinskoi shkoly. 2020;1(27):21–26. (In Russ.)
  21. Sorokina YuA, Zanozina OV, Makarova EV, et al. Leptin and its receptor gene polymorphism as a target for pharmacotherapy in T2DM and COPD. Medical Council. 2021;(7):88–94. doi: 10.21518/2079-701X-2021-7-88-94
  22. Waumans Y, Baerts L, Kehoe K, et al. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol 2015;6:387. doi: 10.3389/fimmu.2015.00387
  23. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076–2082. doi: 10.2337/dc12-1436
  24. Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. doi: 10.1155/2016/3094642
  25. Rakhmat II, Kusmala YY, Handayani DR, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) — A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021;15(3):777–782. doi: 10.1016/j.dsx.2021.03.027
  26. Xu J, Wang J, He M, et al. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest. 2018;98(10):1333–1346. doi: 10.1038/s41374-018-0080-1
  27. Patoulias D, Doumas M. Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies. Endocrinol Metab (Seoul). 2021;36(4):904–908. doi: 10.3803/EnM.2021.1048
  28. Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41(3): bnaa011. doi: 10.1210/endrev/bnaa011
  29. Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabet Metab. 2021;47(2):101213. doi: 10.1016/j.diabet.2020.11.005
  30. Qi F, Qian S, Zhang S, et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135–140. doi: 10.1016/j.bbrc.2020.03.044
  31. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9(1): 601–604. doi: 10.1080/22221751.2020.1739565
  32. Nyland JE, Raja-Khan NT, Bettermann K, et al. Diabetes, drug treatment, and mortality in COVID-19: a multinational retrospective cohort study. Diabetes. 2021;70(12):2903–2916. doi: 10.2337/db21-0385
  33. Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021;20(1):543–550. doi: 10.1007/s40200-021-00777-4
  34. Baggio LL, Varin EM, Koehler JA, et al. Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. Nature Commun. 2020;11(1):3766. doi: 10.1038/s41467-020-17556-z
  35. Chandra R. The role of pharmacogenomics in precision medicine // Medical Laboratory Observer. 2017. [cited 2022 Feb 26] Available from: https://www.mlo-online.com/continuing-education/article/13009247/the-role-of-pharmacogenomics-in-precision-medicine
  36. Nasykhova YA, Tonyan ZN, Mikhailova AA, et al. Pharmacogenetics of type 2 diabetes — progress and prospects. Int J Mol Sci. 2020;21(18):6842. doi: 10.3390/ijms21186842
  37. Wu F, Yang L, Hang K, et al. Full-length human GLP-1 receptor structure without orthosteric ligands. Nature Commun. 2020;11(1):1272. doi: 10.1038/s41467-020-14934-5
  38. Űrgeová A, Javorský M, Klimčáková L, et al. Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors. Pharmacogenomics. 2020;21(5):317–323. doi: 10.2217/pgs-2019-0147
  39. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117(8):2155–2163. doi: 10.1172/JCI30706
  40. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320–323. doi: 10.1038/ng1732
  41. Zimdahl H, Ittrich C, Graefe-Mody U, et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 2014;57(9):1869–1875. doi: 10.1007/s00125-014-3276-y
  42. Wilson JR, Shuey MM, Brown NJ, et al. Hypertension and type 2 diabetes are associated with decreased inhibition of dipeptidyl peptidase-4 by sitagliptin. J Endocr Soc. 2017;1(9):1168–1178. doi: 10.1210/js.2017-00312
  43. GENOCARD Genetic Encyclopedia [Internet]. rs163184 T>G mutation in the KCNQ1 gene [cited 2022 Feb 26]. Available from: https://www.genokarta.ru/snps/rs163184_TG
  44. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs. Diabetologia. 2021;64(6):1201–1212. doi: 10.1007/s00125-021-05402-w
  45. Gotthardová I, Javorský M, Klimčáková L, et al. KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Res Clin Pract. 2017;130:142–147. doi: 10.1016/j.diabres.2017.05.018
  46. Gao K, Wang J, Li L, et al. Polymorphisms in four genes (KCNQ1 rs151290, KLF14 rs972283, GCKR rs780094 and MTNR1B rs10830963) and their correlation with type 2 diabetes mellitus in han chinese in Henan Province, China. Int J Environ Res Public Health. 2016;13(3):260. doi: 10.3390/ijerph13030260
  47. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–990. doi: 10.1038/ng.2383
  48. Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 2013;62(9):3275–3281. doi: 10.2337/db13-0227
  49. PRKD1 Gene [Internet]. GeneCards: The Human Gene Database [cited 2022 Feb 26]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRKD1
  50. CDKAL1 Gene [Internet]. GeneCards: The Human Gene Database [cited 2022 Feb 26]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDKAL1
  51. IL6 Gene [Internet]. GeneCards: The Human Gene [cited 2022 Feb 26]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL6#summaries
  52. Urakov AL, Urakova NA. COVID-19: Cause of death and medications. International Journal of Comprehensive and Advanced Pharmacology. 2020;5(2):45–48. doi: 10.18231/j.ijcaap.2020.011
  53. Vashchenko VI, Vilyaninov VN, Shabanov PD. Strategies for search of pharmacological drugs against SARS-CoV-2 on the base of studying the structural-genetic features of coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(4):269–296. doi: 10.17816/RCF184269-296
  54. Kozlova AS, Pyatibrat AO, Buznik GV, et al. Probable molecular genetic predictors for development of the locomotor system pathology in the extreme physical exertion. Reviews on Clinical Pharmacology and Drug Therapy. 2015;13(3):53–62. doi: 10.17816/RCF13353-62

Copyright (c) 2022 Gurevich K.G., Sorokina Y.A., Urakov A.L., Sinyushkina S.D., Pryazhnikova M.I., Gorinova A.V., Lovtsova L.V., Zanozina O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».